尤瑞克林治疗急性脑梗死患者的疗效和安全性评价
|
摘要
目的探索尤瑞克林对急性脑梗死患者的临床疗效及对神经功能的影响,并评价其安全性。方法选取2015年5月—2017年5月在宁波市镇海龙赛医院就诊的60例急性脑梗死患者,采用随机数字表法将患者分为2组,对照组接受一般常规治疗方案,治疗组同时加用尤瑞克林0.15 U生理盐水100 mL静脉滴入,1次/d,共14 d。比较2组治疗前后的血常规、血糖、血脂、肝肾功能及心肌酶等,分别评估患者的病残程度和神经功能,并观察2组患者临床疗效及不良反应发生情况。结果 2组患者治疗前后血常规、肝肾功能和心肌功能均无显著变化,且两组治疗后各项指标相比,差异不具有统计学意义(P>0.05)。2组患者在接受治疗后2周,NHISS评分、病残程度评分均较治疗前降低,且治疗组显著优于对照组,差异具有统计学意义(P<0.05)。对照组在研究结束时,治疗组患者临床疗效优于对照组,差异具有统计学意义(U=2.742,P=0.006)。治疗期间,治疗组发生不良反应2例(发热1例,心律失常1例),发生率为6.7%;对照组发生不良反应3例(发热1例,低血压1例,心悸1例),发生率为10.0%,差异无统计学意义(χ~2=0.218,P=0.640)。结论尤瑞克林可改善急性脑梗死患者梗死后的神经功能缺损,并提高临床疗效。
Objective To investigate the efficacy and security of urinarykallid in treatment of acute cerebral infarction and effects on nerve function. Methods Sixty patients with acute cerebral infarction were admitted to our hospital from May 2015 to May 2017. Patients were divided to treatment group and control group by the random number table. The control group was given conventional treatment. Patients in the treatment group were also given intravenous infusion of uninary kallid 0.15 U normal saline 100 mL once daily for 14 days. The blood routine, blood glucose, blood lipids, liver and kidney function, and myocardial enzymes before and after treatment were compared. And the efficacy and incidence of adverse drug reactions of two groups were observed. Results There were no significant changes in blood routine, liver and kidney function and myocardial function before and after treatment in the two groups, and there was no significant difference between the two groups after treatment(P>0.05). Two weeks after treatment, the NHISS score and the disability score were lower than those before treatment, and the treatment group was significantly better than the control group, the difference was statistically significant(P<0.05). At the end of the study. The difference was not statistically significant between the two groups(U=2.742,P=0.006). During the treatment, 2 cases of adverse reactions occurred in the treatment group(1 case of fever, 1 case of arrhythmia), the incidence rate was 6.7%; 3 cases of adverse reactions occurred in the control group(1 case of fever, 1 case of hypotension, 1 case of palpitations), occurred The rate was 10.0%, and the difference was not statistically significant(χ~2=0.218, P=0.640). Conclusion Urinarykalid in treatment of acute brain infarction can effectively improve the nerve function of patients and improve the total treatment effectiveness of patients.
Objective To investigate the efficacy and security of urinarykallid in treatment of acute cerebral infarction and effects on nerve function. Methods Sixty patients with acute cerebral infarction were admitted to our hospital from May 2015 to May 2017. Patients were divided to treatment group and control group by the random number table. The control group was given conventional treatment. Patients in the treatment group were also given intravenous infusion of uninary kallid 0.15 U normal saline 100 mL once daily for 14 days. The blood routine, blood glucose, blood lipids, liver and kidney function, and myocardial enzymes before and after treatment were compared. And the efficacy and incidence of adverse drug reactions of two groups were observed. Results There were no significant changes in blood routine, liver and kidney function and myocardial function before and after treatment in the two groups, and there was no significant difference between the two groups after treatment(P>0.05). Two weeks after treatment, the NHISS score and the disability score were lower than those before treatment, and the treatment group was significantly better than the control group, the difference was statistically significant(P<0.05). At the end of the study. The difference was not statistically significant between the two groups(U=2.742,P=0.006). During the treatment, 2 cases of adverse reactions occurred in the treatment group(1 case of fever, 1 case of arrhythmia), the incidence rate was 6.7%; 3 cases of adverse reactions occurred in the control group(1 case of fever, 1 case of hypotension, 1 case of palpitations), occurred The rate was 10.0%, and the difference was not statistically significant(χ~2=0.218, P=0.640). Conclusion Urinarykalid in treatment of acute brain infarction can effectively improve the nerve function of patients and improve the total treatment effectiveness of patients.
引文
[1] 卫生部疾病控制司中华医学会神经病学分会.中国脑血管病防治指南[M].北京:人民卫生出版社,2005:30-36.
[2] 饶明俐.中国脑血管病防治指南:试行版[M].北京:人民卫生出版社,2007:50-51.
[3] 肖文,蒲晓龙,柏杖勇,等.动静脉联合溶栓与机械取栓治疗急性脑梗死的临床疗效及对患者预后的影响[J].河北医学,2017,23(9):1498-1502.
[4] 郭玉兰.尤瑞克林在不同亚型急性脑梗死中的治疗效果观察[J].贵州医药,2016,40(6):598-600.
[5] 白伟利,侯瑞生,秦伟伟,等.尤瑞克林治疗分水岭脑梗死效果及其对血清S-100B蛋白及神经元特异性烯醇化酶的影响[J].中华实用诊断与治疗杂志,2016,30(6):617-619.
[6] SACCO R L,KASNER S E,BRODERICK J P,et al.An updated definition of stroke for the 21st century:a statement for healthcare professionals from the American Heart Association/American Stroke Association[J].Stroke,2013,44(7):2064-2089.
[7] 林鹤,阮海威,王树,等.动脉自旋标记灌注成像在缺血性脑血管病中的应用价值(附50例分析)[J].福建医药杂志,2016,38(3):102-105.
[8] 中华医学会神经病学分会,中华医学会神经病分会脑血管病组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):248.
[9] 李佳佳,马征.TOAST分型与急性脑梗死患者近期预后的关系[J].实用临床医药杂志,2018,22(1):58-60.
[10] 魏鹏.尤瑞克林治疗不同TOAST亚型脑梗死的疗效观察[J].临床合理用药杂志,2018,11(8):46-47.
[11] 史哲,张茗,翟继红,王拥军.尤瑞克林治疗急性脑梗死效果的CISS分型评价[J].北京医学,2014,36(05):391-392.
[12] 李爱芹.尤瑞克林治疗急性脑梗死临床疗效观察[J].河北医学,2014,20(12):2090-2092.
[13] 李兵,胡世颉,闫志强,等.尤瑞克林和依达拉奉联合治疗急性脑梗死患者的临床效果及安全性[J].中国医药,2017,12(6):865-868.
[14] 杜翔,薛常虎.尤瑞克林在不同TOAST分型急性脑梗死临床治疗中应用观察[J].陕西医学杂志,2013,42(7):869-870.
[15] 巩企霞,眭建,赵晶.尤瑞克林治疗不同TOAST分型急性脑梗死的临床疗效观察[J].中国医药指南,2013,11(5):5-8.
[16] MIAO J,DENG F,ZHANG Y,et al.Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic stroke[J].Neurosciences,2016,21(2):126-130.
[17] JIANG K,MOU J.Analysis of treatment effect of urinary kallidinogenase combined with edaravone on massive cerebral infarction[J].Biomedical Reports,2016,5(2):155-158.
[18] 黄家星,林文华,刘丽萍,等.缺血性卒中侧支循环评估与干预中国专家共识[J].中国卒中杂志,2013,8(4):285-293.
[19] ZHANG H,KANG T,LI L,et al.Electroacupuncture reduces hemiplegia following acute cerebral artery infarction with alteration of serum NSE,S-100B and endothelin[J].Curr Neurovasc Res,2013,10(3):216-221.
[20] 韦朝霞,祁风,刘祖佑,等.尤瑞克林治疗急性脑梗死的临床疗效及安全性[J].山东医药,2013,53(5):79-80.
[2] 饶明俐.中国脑血管病防治指南:试行版[M].北京:人民卫生出版社,2007:50-51.
[3] 肖文,蒲晓龙,柏杖勇,等.动静脉联合溶栓与机械取栓治疗急性脑梗死的临床疗效及对患者预后的影响[J].河北医学,2017,23(9):1498-1502.
[4] 郭玉兰.尤瑞克林在不同亚型急性脑梗死中的治疗效果观察[J].贵州医药,2016,40(6):598-600.
[5] 白伟利,侯瑞生,秦伟伟,等.尤瑞克林治疗分水岭脑梗死效果及其对血清S-100B蛋白及神经元特异性烯醇化酶的影响[J].中华实用诊断与治疗杂志,2016,30(6):617-619.
[6] SACCO R L,KASNER S E,BRODERICK J P,et al.An updated definition of stroke for the 21st century:a statement for healthcare professionals from the American Heart Association/American Stroke Association[J].Stroke,2013,44(7):2064-2089.
[7] 林鹤,阮海威,王树,等.动脉自旋标记灌注成像在缺血性脑血管病中的应用价值(附50例分析)[J].福建医药杂志,2016,38(3):102-105.
[8] 中华医学会神经病学分会,中华医学会神经病分会脑血管病组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):248.
[9] 李佳佳,马征.TOAST分型与急性脑梗死患者近期预后的关系[J].实用临床医药杂志,2018,22(1):58-60.
[10] 魏鹏.尤瑞克林治疗不同TOAST亚型脑梗死的疗效观察[J].临床合理用药杂志,2018,11(8):46-47.
[11] 史哲,张茗,翟继红,王拥军.尤瑞克林治疗急性脑梗死效果的CISS分型评价[J].北京医学,2014,36(05):391-392.
[12] 李爱芹.尤瑞克林治疗急性脑梗死临床疗效观察[J].河北医学,2014,20(12):2090-2092.
[13] 李兵,胡世颉,闫志强,等.尤瑞克林和依达拉奉联合治疗急性脑梗死患者的临床效果及安全性[J].中国医药,2017,12(6):865-868.
[14] 杜翔,薛常虎.尤瑞克林在不同TOAST分型急性脑梗死临床治疗中应用观察[J].陕西医学杂志,2013,42(7):869-870.
[15] 巩企霞,眭建,赵晶.尤瑞克林治疗不同TOAST分型急性脑梗死的临床疗效观察[J].中国医药指南,2013,11(5):5-8.
[16] MIAO J,DENG F,ZHANG Y,et al.Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic stroke[J].Neurosciences,2016,21(2):126-130.
[17] JIANG K,MOU J.Analysis of treatment effect of urinary kallidinogenase combined with edaravone on massive cerebral infarction[J].Biomedical Reports,2016,5(2):155-158.
[18] 黄家星,林文华,刘丽萍,等.缺血性卒中侧支循环评估与干预中国专家共识[J].中国卒中杂志,2013,8(4):285-293.
[19] ZHANG H,KANG T,LI L,et al.Electroacupuncture reduces hemiplegia following acute cerebral artery infarction with alteration of serum NSE,S-100B and endothelin[J].Curr Neurovasc Res,2013,10(3):216-221.
[20] 韦朝霞,祁风,刘祖佑,等.尤瑞克林治疗急性脑梗死的临床疗效及安全性[J].山东医药,2013,53(5):79-80.